TAIM
NBIX icon

TD Ameritrade Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

TD Ameritrade Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-74
Closed -$7K – 313
2023
Q2 		$7K Sell
74
-33
-31% -$3.22K ﹤0.01% 380
2023
Q1 		$11K Sell
107
-43
-29% -$4.47K ﹤0.01% 368
2022
Q4 		$18K Buy
+150
New +$17.6K ﹤0.01% 332
2022
Q3 		– Sell
-305
Closed -$30K – 625
2022
Q2 		$30K Sell
305
-189
-38% -$17.4K ﹤0.01% 344
2022
Q1 		$46K Sell
494
-38
-7% -$3.22K ﹤0.01% 362
2021
Q4 		$45K Buy
+532
New +$48.9K ﹤0.01% 358

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Ameritrade Investment Management's NBIX Position: Q3 2023 in Review

TD Ameritrade Investment Management sold out of Neurocrine Biosciences (NBIX) in Q3 2023, closing a stake of 74 shares — an estimated $7K sold.

TD Ameritrade Investment Management first reported a position in NBIX in Q4 2021 and held it in 6 quarters. The position peaked at $46K in Q1 2022. 512 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

  • TD Ameritrade Investment Management reported no remaining Neurocrine Biosciences position as of Q3 2023 after selling out during the quarter.
  • TD Ameritrade Investment Management sold 74 Neurocrine Biosciences shares in Q3 2023, an estimated $7K.
  • TD Ameritrade Investment Management first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 6 quarters.
  • TD Ameritrade Investment Management's Neurocrine Biosciences position peaked at $46K in Q1 2022.
  • 512 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on TD Ameritrade Investment Management's 13F filing for Q3 2023.